Among the most relevant ones, NT-proBNP has been the biomarker with the best performance to detect and predict adverse outcomes in patients with CCM, showing an unparalleled discriminative capacity compared with other biomarkers (30–33). This evidence concerns the gene NPPB and cerebral cavernous malformation.